MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

KalVista Pharmaceuticals Inc

Closed

SectorHealthcare

12.87 3.62

Overview

Share price change

24h

Current

Min

12.3

Max

13.1

Key metrics

By Trading Economics

Income

-6.2M

-49M

EPS

-0.92

Profit margin

-3,702.322

Employees

150

EBITDA

4.4M

-41M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+119.92% upside

Dividends

By Dow Jones

Next Earnings

10 lip 2025

Market Stats

By TradingEconomics

Market Cap

4.6M

597M

Previous open

9.25

Previous close

12.87

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

KalVista Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 lis 2024, 21:11 UTC

Major Market Movers

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering

Peer Comparison

Price change

KalVista Pharmaceuticals Inc Forecast

Price Target

By TipRanks

119.92% upside

12 Months Forecast

Average 27.38 USD  119.92%

High 39 USD

Low 19 USD

Based on 10 Wall Street analysts offering 12 month price targets forKalVista Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

11.76 / 12.52Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.